Search

everythinglearnresearchcommunity

for

Search:↓

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.

MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.

Cutaneous lymphocytosis in cats is a slowly progressing, relatively benign disease affecting older cats, often causing skin lesions and systemic signs.

Cyclosporine A can reduce inflammation in dogs with sebaceous adenitis, but ongoing treatment is needed.

Serum granulysin levels can indicate the activity and prognosis of alopecia areata.

The combination of oral PUVA and corticosteroids helps regrow hair in severe alopecia areata.

Both treatments for alopecia areata are equally effective and safe.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.

Leptin-deficient mice, used as a model for Type 2 Diabetes, have delayed wound healing due to impaired contraction and other dysfunctional cellular responses.

A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.

Unconventional lymphocytes are important for quick immune responses and healing of skin and mucosal barriers.

The model showed that immune system guardians and the cytokine interferon-γ are key in alopecia areata progression.

A new mouse model for vitiligo helps study immune responses and potential treatments.

Alopecia areata may be caused by the immune system attacking hair follicles.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

Radiation therapy damages skin structure and immune function, causing inflammation and potential hair loss.

Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.

An 8-year-old girl developed a rare skin condition in a linear pattern on one side of her body after a lung infection, which improved with treatment.

A man with a type of skin lymphoma had unusual yellowish skin growths despite normal blood lipid levels, and treatment reduced some symptoms but not the growths.

Too much IKZF1 and Ikaros protein may cause alopecia areata.

Being allergic to linalool, a common fragrance ingredient, might contribute to developing frontal fibrosing alopecia.

The study found that a key immune pathway protecting hair follicles is reduced in a mouse model of scarring hair loss.

Key genes linked to immune response are upregulated in hair follicles and skin tissues in chronic discoid lupus erythematosus.

Key genes linked to immune response are highly active in lupus-affected hair follicles.

Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.

Simvastatin reduces inflammation and promotes hair regrowth in alopecia areata.

Melanogenesis-related proteins may trigger immune responses in alopecia areata patients.